Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cells for Psoriasis: How They Compare With Medicines
Transcript
- 0:00SPEAKER_00: Welcome to the Sorona Cell Podcast.
- 0:02SPEAKER_00: Imagine your immune system acting like a home security system that simply will not stop blaring.
- 0:08SPEAKER_01: Aaron Powell Like the motion detectors are just overly sensitive.
- 0:11SPEAKER_00: Aaron Ross Powell And the sirens are going off constantly and there is no obvious threat.
- 0:15SPEAKER_00: For anyone navigating an autoimmune condition, that is often a daily, deeply frustrating reality.
- 0:21SPEAKER_01: You feel like you have exhausted the standard options.
- 0:24SPEAKER_00: So the search for alternatives begins, but the landscape of medical information out there is, well, it is completely overwhelming.
- 0:31SPEAKER_00: So today, the mission of this deep dive is to unpack a comprehensive guide that places experimental stem cell studies side by side with standard medical evidence.
- 0:41SPEAKER_01: The goal is to give you a clear, unfiltered look at what the research actually says.
- 0:45SPEAKER_00: We are taking a very close look at an experimental approach currently being discussed for the treatment of psoriasis and comparing it directly to established, widely used medicines.
- 0:55SPEAKER_01: The intention today is to provide a grounded, evidence-based comparison.
- 0:59SPEAKER_01: We are not here to pick a winner or promote one path over another.
- 1:03SPEAKER_00: The objective is to empower you with clear, factual contrast so you understand exactly where the science currently stands.
- 1:10SPEAKER_01: When evaluating medical data, we have to look closely at the strength of the evidence, the size of the studies, the presence of comparison groups.
- 1:18SPEAKER_00: Aaron Powell And what the researchers themselves are concluding about the limitations of their own work.
- 1:23SPEAKER_01: Let us start with the baseline of what is happening in the body before we even get to the interventions.
- 1:29SPEAKER_00: For anyone trying to make sense of these experimental selves, what is the theoretical mechanism here?
- 1:34SPEAKER_00: Like what are they actually trying to change in that biological environment?
- 1:38SPEAKER_01: Aaron Powell Well, when you look at psoriasis, um, it is fundamentally an autoimmune disease.
- 1:43SPEAKER_00: I see.
- 1:43SPEAKER_01: And if we look at Cochrane's plain language review of these medicines, they explain it in a very straightforward way.
- 1:49SPEAKER_01: The immune system is essentially uh speeding up skin cell growth.
- 1:53SPEAKER_00: Aaron Powell Like putting it into overdrive.
- 1:56SPEAKER_01: It becomes rapid, uncontrolled growth that builds up.
- 1:59SPEAKER_01: It forms these raised, um, scaly patches on the skin.
- 2:03SPEAKER_00: Aaron Ross Powell And those are what we call plaques?
- 2:05SPEAKER_01: Yes, the plaques.
- 2:07SPEAKER_01: So the experimental treatment being studied to address this involves delivering donor cells.
- 2:12SPEAKER_00: Aaron Powell Usually what are known as mesenchymal stem cells.
- 2:16SPEAKER_01: These are harvested from adult tissue, um like bone marrow, or they can come from the human umbilical cord.
- 2:22SPEAKER_00: Aaron Powell The working theory among researchers testing this approach is that these donor cells release a mix of growth factors.
- 2:30SPEAKER_01: Hoping that may calm the underlying inflammation and shift the overall balance of the immune cells.
- 2:36SPEAKER_00: I am looking at the specific immune cells mentioned in the sources, and two types stand out: regulatory T cells and TH17 cells.
- 2:45SPEAKER_01: The interaction between those specific cells is the core of the biological mechanism.
- 2:50SPEAKER_00: Aaron Ross Powell How do those two interact in someone dealing with these plaques?
- 2:54SPEAKER_01: Regulatory T cells are essentially the peacekeepers.
- 2:57SPEAKER_01: They are responsible for calming other immune cells down.
- 3:00SPEAKER_00: Aaron Ross Powell While TH17 cells, on the other hand, along with a chemical signal called interleukin-17, are the ones driving the severe inflammation seen in psoriasis.
- 3:11SPEAKER_01: The sources detail a 2022 trial where researchers actually measured these specific cells in the patient's blood.
- 3:17SPEAKER_00: They found that the calming regulatory T cells actually rose in the people who seemed to respond to the experimental treatment.
- 3:25SPEAKER_01: At the same time, the inflammatory TH17 cells and that interleukin-17 signal fell.
- 3:31SPEAKER_00: Let's think about this like that home security system from earlier.
- 3:34SPEAKER_01: Aaron Powell The glitchy one.
- 3:35SPEAKER_00: The glitch causing the alarms to blare constantly, creating all that chaos and inflammation in the house.
- 3:41SPEAKER_00: That is the TH17 cells and the interleukin-17 signals.
- 3:45SPEAKER_01: Aaron Powell And so the mesenchemal stem cells are theoretically acting like technicians sent into the house to fix the wiring.
- 3:52SPEAKER_00: Aaron Powell And the technicians they deploy are the regulatory T cells working to turn off the sirens and restore quiet.
- 4:00SPEAKER_01: But hold on.
- 4:02SPEAKER_01: Just because we see the technicians arrive on a blood test and we see the alarms quiet down in the bloodstream, that does not definitively prove the technicians are the reason the actual physical damage to the house is repaired.
- 4:15SPEAKER_01: We are just seeing activity in the blood.
- 4:17SPEAKER_01: This raises a fundamental issue in medical research regarding causality.
- 4:22SPEAKER_00: Observing a shift in blood markers is certainly a biological signal.
- 4:26SPEAKER_01: It suggests a potential mechanism of action is occurring.
- 4:29SPEAKER_01: However, as the source text explicitly states, these blood changes do not prove the experimental cells actually caused the skin to clear up.
- 4:37SPEAKER_00: Without a dedicated comparison group in these early small trials, researchers cannot definitively separate the effect of the experimental cells from other potential causes of improvement.
- 4:48SPEAKER_01: If the experimental route is currently just showing us biological signals without clinical proof of causality, we have to look at the established heavyweight champion it is competing against.
- 5:19SPEAKER_01: The review overwhelmingly found that biologic medicines cleared skin significantly better than older traditional tablets.
- 5:27SPEAKER_00: In biologics, um, they are complex proteins.
- 5:30SPEAKER_01: Designed to block very specific inflammation signals in the body.
- 5:34SPEAKER_00: Things like interleukin-17.
- 5:36SPEAKER_01: Or interleukin-23 and TNF alpha.
- 5:40SPEAKER_01: In that massive 2024 search, the top five biologics ranked highest for achieving 90% skin clearing.
- 5:46SPEAKER_00: When compared with a placebo.
- 5:48SPEAKER_01: And the data showed very little difference in overall effectiveness between those top five options.
- 6:01SPEAKER_01: It is a massive body of evidence.
- 6:04SPEAKER_00: If the established biologics are achieving those kinds of numbers, why are researchers even spending time and money looking for experimental alternatives?
- 6:11SPEAKER_01: Because the evidence for standard medicines, while massive, has heavily documented limits.
- 6:17SPEAKER_00: Limits that researchers are very aware of.
- 6:19SPEAKER_01: First, the studies included in the Cochrane review were quite short.
- 6:23SPEAKER_00: Lasting only two to six months.
- 6:25SPEAKER_01: Second, there is a profound financial influence present in the data.
- 6:29SPEAKER_01: Drug companies directly funded 157 of the 177 studies that explicitly named a funder.
- 6:46SPEAKER_01: How can anyone truly know the long-term reality for a patient living with this day in and day out, year after year?
- 6:53SPEAKER_00: Outside of a heavily controlled corporate-funded six-month window.
- 6:57SPEAKER_01: Additionally, the studies reported serious harms unevenly, which led Cochrane's authors to express uncertainty about whether the safety profile truly differs between the various biologic medicines.
- 7:08SPEAKER_00: Furthermore, many of the participants in these studies had severe psoriasis at the baseline.
- 7:13SPEAKER_01: Meaning the results may not necessarily apply to individuals navigating milder forms of the disease.
- 7:25SPEAKER_01: The data is undeniably huge, but it is bounded by some very restrictive parameters.
- 7:31SPEAKER_00: Those specific gaps in standard care, combined with the reality that biologics simply do not work for everyone, explain why researchers are actively testing mesenchemal stem cells as an experimental alternative.
- 7:43SPEAKER_01: Let us look at what the human trials for these experimental cells actually report.
- 7:47SPEAKER_00: The human evidence for stem cells in this context comes from very small, purely experimental studies.
- 7:53SPEAKER_01: The guide details a 2022 trial published in Signal Transduction and Targeted Therapy.
- 7:58SPEAKER_01: This trial studied just 17 people.
- 8:01SPEAKER_00: Who received infusions of donated umbilical cord cells.
- 8:04SPEAKER_01: Within six months, eight of those 17 people improved their skin scores by at least 40%.
- 8:10SPEAKER_00: At the end of the trial, three of the 17 people had no or minimal disease remaining.
- 8:15SPEAKER_01: The researchers noted a few patterns.
- 8:17SPEAKER_01: Women responded more often than men.
- 8:19SPEAKER_00: And individuals who had lower baseline regulatory T cell levels seemed to respond more often.
- 8:24SPEAKER_01: The researchers also noted they saw no obvious side effects during the treatment or during the six-month follow-up period.
- 8:30SPEAKER_00: But the groups are too small for concrete conclusions.
- 8:33SPEAKER_01: The sources also outline a more recent 2025 case series involving three women with hard-to-treat psoriasis.
- 8:40SPEAKER_00: They each received two cord cell infusions spaced one week apart.
- 8:44SPEAKER_01: The best responder in that incredibly small group saw an 87% lower skin score at week four.
- 8:51SPEAKER_00: And the researchers categorize the cells as well tolerated.
- 8:55SPEAKER_00: But looking at the structure of these studies, the missing piece is glaring.
- 9:00SPEAKER_01: Neither the 2022 trial of 17 people nor the 2025 case series of three women had a comparison group.
- 9:08SPEAKER_00: I mean, think about starting a totally new health routine.
- 9:11SPEAKER_01: Okay.
- 9:12SPEAKER_00: If you begin a strict new diet and you start getting a perfect eight hours of sleep every night, and you take a brand new daily supplement all at the exact same time?
- 9:22SPEAKER_01: It is a lot of variables.
- 9:24SPEAKER_00: So how do you know the supplement is the specific variable making you feel better?
- 9:29SPEAKER_01: You simply do not.
- 9:31SPEAKER_01: How can researchers confidently attribute any of this skin clearing to the experimental cells without a placebo group standing by for comparison?
- 9:38SPEAKER_00: Aaron Powell They cannot make that definitive attribution.
- 9:41SPEAKER_00: And the researchers acknowledge this limitation.
- 9:44SPEAKER_01: The authors of the 2025 report explicitly state that much larger studies are needed before any concrete conclusions can be drawn.
- 9:51SPEAKER_00: Aaron Powell Without a control group separating the specific clinical effect of the experimental cells from other variables like spontaneous remission, unrecorded lifestyle changes, or concurrent treatments is scientifically impossible.
- 10:02SPEAKER_01: The results suggest biological potential, but they absolutely do not prove clinical efficacy.
- 10:08SPEAKER_00: Having explored the theoretical mechanisms, the massive data behind standard medicines, and the very early experimental trials, it is time to put these two bodies of evidence into a direct side-by-side reality check.
- 10:21SPEAKER_01: This contrast really illuminates why doctors still lead with standard care.
- 10:25SPEAKER_00: Contrasting the data directly reveals a monumental gap in the evidence base.
- 10:29SPEAKER_00: On one side, standard biologic medicines are supported by robust data.
- 10:33SPEAKER_01: From 67,889 adults across 204 highly structured studies.
- 10:40SPEAKER_00: On the other side, the experimental cell studies discussed in our sources encompass a total of just 20 individuals.
- 10:46SPEAKER_01: 17 in one trial and three in a case series.
- 10:49SPEAKER_00: The standard medicine studies largely utilize placebo comparison groups to prove efficacy.
- 10:54SPEAKER_01: The experimental cell studies had absolutely none.
- 10:58SPEAKER_01: Standard care operates on well-established, globally recognized protocols.
- 11:02SPEAKER_00: While stem cell therapy remains entirely experimental with no standardized approach.
- 11:08SPEAKER_01: For listeners trying to understand how these experimental options exist in the real world, Sarona Cell is a regenerative medicine center located in Kuala Lumpur.
- 11:16SPEAKER_00: Serving both local and international patients.
- 11:19SPEAKER_01: And arranging treatments at partner facilities there in Kuala Lumpur.
- 11:23SPEAKER_00: The center states that it works specifically with umbilical cord-derived Wharton's jelly mesenchymal stem cells.
- 11:29SPEAKER_01: Often referred to as WJMSCs.
- 11:32SPEAKER_01: We must firmly clarify a crucial scientific point regarding that clinical data, though.
- 11:37SPEAKER_00: The studies we are analyzing today used their own specific laboratory cells cultivated for their distinct trials.
- 11:45SPEAKER_01: So the results, the data, and the observations from the 2022 trial and the 2025 case series, they do not automatically apply to Sorona cells WJMSCs.
- 11:56SPEAKER_00: Aaron Powell Or to any one specific provider cells anywhere globally.
- 11:59SPEAKER_01: Aaron Powell Because the cell culture techniques, the expansion methods, and the freezing protocols vary significantly between different laboratories.
- 12:07SPEAKER_00: Meaning the experimental product is never exactly the same from one facility to the next.
- 12:13SPEAKER_01: Given this highly experimental status and the complete lack of standard protocols, how does an intervention like this actually fit into a patient's journey?
- 12:22SPEAKER_00: There is a 2022 systematic review mentioned in the sources that looked at 69 studies on mesenchymal cells and psoriasis.
- 12:30SPEAKER_01: Mostly covering lab work, animal models, and small human reports.
- 12:35SPEAKER_00: The authors of that comprehensive review concluded that the extremely wide range of cell types and delivery methods makes a standard protocol impossible for now.
- 12:45SPEAKER_01: What are the specific blind spots patients and doctors are dealing with here?
- 12:48SPEAKER_00: Aaron Powell The major unknowns in this experimental field encompass almost every variable of the treatment.
- 12:54SPEAKER_01: Researchers do not yet know the most effective cell source, the proper dosage, the expected duration of any potential effect.
- 13:01SPEAKER_00: Aaron Powell Or the long-term safety implications of repeat treatments.
- 13:05SPEAKER_01: Because researchers used entirely different mesenchymal stem cell treatment plans across the various small studies, the data cannot be pulled together to create a cohesive, reliable protocol.
- 13:15SPEAKER_00: The 2022 review also lists potential severe risks.
- 13:19SPEAKER_01: Including local skin reactions and graft versus host disease, which is a serious condition where the donor cells actually trigger an immune attack against the recipient's own body.
- 13:28SPEAKER_00: Furthermore, since the human trials only followed patients for up to six months, any later complications or long-term safety profiles remained entirely unknown.
- 13:38SPEAKER_01: The interaction between this experimental therapy and standard care in the 2025 K series is particularly fascinating.
- 13:45SPEAKER_00: The three women involved had previously not responded to several standard biologics.
- 13:50SPEAKER_01: But after receiving the experimental cell infusions, their treatment paths took an unexpected turn.
- 13:55SPEAKER_00: Two of the women actually returned to their previous biologics at week nine.
- 13:59SPEAKER_02: And they reportedly responded better to those medicines than they had previously.
- 14:04SPEAKER_00: The third woman switched to an entirely new biologic at week 24.
- 14:08SPEAKER_01: The experimental stem cells did not replace the standard medicines at all.
- 14:12SPEAKER_00: They seemingly worked alongside them.
- 14:14SPEAKER_01: It is almost as if the cells act as a reboot button for the immune system.
- 14:19SPEAKER_00: Perhaps the experimental infusion clears the glitched cache, making the immune system receptive to the standard established medicines again.
- 14:26SPEAKER_01: Rather than acting as a standalone permanent solution.
- 14:30SPEAKER_00: If we connect that specific observation to the broader picture of autoimmune research, the authors of that case series suggest the experimental cells may temporarily reset the immune response.
- 14:42SPEAKER_01: This hypothesis is supported by the finding of more calming regulatory T cells in the blood as the patient's skin temporarily improved.
- 14:50SPEAKER_00: However, it is vital to note that no clinical trial has yet tested whether experimental cells and standard biologics work better together than biologics alone.
- 14:59SPEAKER_00: The case series raises an interesting hypothesis about immune modulation.
- 15:04SPEAKER_02: But observations from three individuals cannot provide a definitive medical answer.
- 15:08SPEAKER_00: We arrive at a very clear synthesis of the evidence.
- 15:11SPEAKER_00: The comprehensive guide paints a stark contrast between two very different worlds of medicine.
- 15:17SPEAKER_02: Standard medicines, particularly the biologics, possess massive placebo-backed evidence demonstrating high rates of skin clearing.
- 15:25SPEAKER_00: However, we have to acknowledge that this established care is bounded by short study durations, heavy pharmaceutical industry funding, and the everyday reality that these medicines simply do not work perfectly for everyone.
- 15:37SPEAKER_01: On the other side, stem cell therapy remains a highly experimental, small-scale frontier.
- 15:43SPEAKER_00: The early data suggests intriguing biological activity and potential skin improvement, but the studies completely lack comparison groups.
- 15:51SPEAKER_01: They lack long-term safety data and standardized protocols.
- 15:55SPEAKER_00: The immune system's memory is incredibly complex and deeply entrenched.
- 15:59SPEAKER_01: If temporary experimental cell infusions can theoretically reset an immune response just enough to make previously failed standard medications effective again, what does this tell us about how flexible and trainable our autoimmune systems might actually be?
- 16:14SPEAKER_00: The specific mechanisms governing immune modulation are still being unraveled by researchers.
- 16:19SPEAKER_01: And understanding that flexibility remains one of the most compelling frontiers in modern medical research.
- 16:24SPEAKER_00: That flexibility is a profound concept to consider for the future of autoimmune care.
- 16:28SPEAKER_00: We must firmly remind you that nobody should ever stop, pause, or change their medicines without directly consulting their own doctor.
- 16:36SPEAKER_01: Established medicines remain the definitive standard of care for treating psoriasis.
- 16:41SPEAKER_00: For those who are actively weighing their options and are interested in having their medical reports reviewed to see if experimental therapy may be suitable for their specific situation, you can contact the Sorona Cell team.
- 16:52SPEAKER_01: They can be reached via WhatsApp at plus six zero one eight two two zero zero three two or by email at info at SoronaCell.com.
- 17:03SPEAKER_00: Sorona Cell arranges treatment at their partner facilities in Kuala Lumpur.
- 17:07SPEAKER_00: And you can find the specific steps detailing what follows an inquiry on their How It Works page online.
- 17:13SPEAKER_01: Keep questioning the data.
- 17:15SPEAKER_00: Keep seeking out the clear evidence, and we will catch you on the next deep dive.